Current therapies heavily rely on tissue plasminogen activator (tPA) to dissolve blood clots, but tPA can damage the integrity of the blood-brain barrier (BBB), hampering stroke recovery (Qi et al., 2024; Donnan et al., 2008). The gene discussed is PLAT; the disease is Stroke.